| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/22/2009 | CN101415695A Ceramide kinase modulation |
| 04/22/2009 | CN101415678A Benzo[F]isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists |
| 04/22/2009 | CN101415429A Fat accumulation inhibitor |
| 04/22/2009 | CN101415425A Triglyceride-lowering agent and hyperinsulinism-ameliorating agent |
| 04/22/2009 | CN101413012A Method for inducing differentiation of mesenchyma stem cell into islet beta-like cells, and use thereof |
| 04/22/2009 | CN101412754A Gastrin compositions and formulations, and methods of use and preparation |
| 04/22/2009 | CN101412744A Anti-angiogenic compositions and methods of use thereof |
| 04/22/2009 | CN101412716A Method for extracting lactoflavin |
| 04/22/2009 | CN101412714A Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione maleic acid salt |
| 04/22/2009 | CN101412713A Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione maleic acid salt |
| 04/22/2009 | CN101412711A Carbamate derivatives and use thereof in medicine |
| 04/22/2009 | CN101411851A Chinese medicinal composition for preventing and treating hyperlipemia symptom and atherosclerosis |
| 04/22/2009 | CN101411822A Kidney-tonifying Chinese medicinal formulation for treating diabetes and preparation method thereof |
| 04/22/2009 | CN101411821A Anti-aging medicament for treating coronary heart disease and hyperlipemia, and preparation method thereof |
| 04/22/2009 | CN101411813A Use of Chinese medicinal composition in preparing medicament for treating chronic systolic heart failure |
| 04/22/2009 | CN101411791A Method for preparing total flavones from leaf of Belamcanda rhizome and use |
| 04/22/2009 | CN101411786A Diabetic capsule containing trichosanthin, rhizoma coptidis and ginseng |
| 04/22/2009 | CN101411785A Lotus and hawthorn tea drink for reducing blood fat |
| 04/22/2009 | CN101411781A Use of pu'er tea in preparing medicament for treating or preventing diabetes |
| 04/22/2009 | CN101411765A Use of Chinese medicinal composition in preparing medicament for treating metabolism syndrome |
| 04/22/2009 | CN101411761A Novel use of plants in sorbus malus group of malus |
| 04/22/2009 | CN101411760A Novel use of plants in sorbus malus group of malus |
| 04/22/2009 | CN101411726A Method for producing pine needle powder |
| 04/22/2009 | CN101411723A Method for producing Paphia undulata amino acid oral liquid |
| 04/22/2009 | CN101411715A Pharmaceutical composition containing acarbose |
| 04/22/2009 | CN101411711A Composition containing alisol A and alisol A 24-acetic ester and use |
| 04/22/2009 | CN101411704A Use of pyrimidine-substituted phenylpropionic acid compound in preparing medicament for preventing and/or treating diabetes |
| 04/22/2009 | CN101411701A Vitamin C microcapsule formulation and preparation method thereof |
| 04/22/2009 | CN101411696A Lysine salt microcapsule formulation and processing technique thereof |
| 04/22/2009 | CN101411693A Oral dosage form for controlled drug release |
| 04/22/2009 | CN101411497A Lipid-lowering pressure-reducing hypoglycemic health tea |
| 04/22/2009 | CN101411495A Health products with fat-reducing efficacy |
| 04/22/2009 | CN100480375C Human cord blood derived unrestricted somatic stem cells (USSC) |
| 04/22/2009 | CN100480253C Alkylamino alkoxyl substituted C-glycosylisoflavones and preparing method and the use of the same |
| 04/22/2009 | CN100480245C 2-amino-4H-3.1-benzoxazinone-4-keto derivatives for treatment of obesity |
| 04/22/2009 | CN100479843C Xiaokezhinian capsule for treating diabetet, hyperlipemia and likes |
| 04/22/2009 | CN100479831C Compositions for preventing or ameliorating multiple risk factor syndromes |
| 04/22/2009 | CN100479808C Fibrate tablet and production method thereof |
| 04/21/2009 | US7521471 CB1cannabinoid receptor antagonists; e.g. 5-(4-chlorophenyl)-4-cyano-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-1H-pyrazole-3-carboxamide; various psychological, neurodegenerative, pain and cardiovascular disorders |
| 04/21/2009 | US7521461 2-{[4-(2-Oxo-2-{[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]methyl}benzoic acid; peroxisome proliferator activated receptors alpha and gamma agonist; antidiabetic agents; Insulin Resistance Syndrome (IRS); cardiovascular disorders; myocardial infarction; stroke; atherosclerosis; dyslipidemia |
| 04/21/2009 | US7521455 Histamine H3 receptor antagonist or inverse agonist activity; metabolic diseases, circulatory diseases, or nervous system diseases; e.g. 3-(4-((1-cyclobutyl-4-piperidinyl)oxy)phenyl)-2-ethylpyrido(2,3-d)pyrimidin-4(3H)-one |
| 04/21/2009 | US7521450 Inhibitors of kinases |
| 04/21/2009 | US7521446 4-({8-[(2,6-Difluorophenyl)amino]-9-cyclopentylpurin-2-yl}amino) trans-cyclohexan-1-ol; mitogen-activated protein (tyrosine) kinase inhibitor; anticarcinogenic, antiinflammatory, analgesic agent, cardiovascular disease, renal disease, autoimmune condition, macular degeneration, pulmonary hypertension |
| 04/21/2009 | US7521430 N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter |
| 04/21/2009 | US7521212 Method for producing oligopolysaccharides |
| 04/21/2009 | US7521069 Methods and compositions for pulmonary delivery of insulin |
| 04/21/2009 | US7521053 Angiopoietin-2 specific binding agents |
| 04/21/2009 | CA2499329C Indole-3-carboxamides as glucokinase (gk) activators |
| 04/21/2009 | CA2362003C Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 04/21/2009 | CA2356263C Aminopyrazole derivatives |
| 04/21/2009 | CA2338358C Compounds and compositions for delivering active agents |
| 04/21/2009 | CA2299420C Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use |
| 04/21/2009 | CA2182949C Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| 04/21/2009 | CA2182034C Treatment for juvenile diabetes |
| 04/16/2009 | WO2009049105A2 Methods for inducing satiation |
| 04/16/2009 | WO2009049022A1 Method for treatment of pancreatitis |
| 04/16/2009 | WO2009048959A1 Rapid acting injectable insulin compositions |
| 04/16/2009 | WO2009048945A1 Rapid mucosal gel or film insulin compositions |
| 04/16/2009 | WO2009048527A1 Substituted biphenyl gpr40 modulators |
| 04/16/2009 | WO2009048148A1 Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine |
| 04/16/2009 | WO2009048128A1 Body weight gain inhibitor |
| 04/16/2009 | WO2009047881A1 Agent for increasing body weight, animal feed for increasing body weight and health food for increasing body weight |
| 04/16/2009 | WO2009047798A2 Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| 04/16/2009 | WO2009047558A1 Benzothiazoles as ghrelin receptor modulators |
| 04/16/2009 | WO2009047330A1 Use of wnt5a for treating or preventing obesity and atherosclerosis |
| 04/16/2009 | WO2009046881A1 Use of a peptide combination including c-peptide, as a therapeutic agent |
| 04/16/2009 | WO2009046880A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046879A2 Use of the combination of npy and nociceptin as a therapeutic agent |
| 04/16/2009 | WO2009046878A1 Tnf inhibitory peptide and cgrp as therapeutic agents |
| 04/16/2009 | WO2009046877A2 Use of a histrelin and leuprolide as therapeutic agents |
| 04/16/2009 | WO2009046876A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046875A2 Combination of splenopentin and thymopentin and the use thereof in medicine |
| 04/16/2009 | WO2009046874A1 Therapeutic combination of trh-potentiating peptide and stresscopin |
| 04/16/2009 | WO2009046873A1 Combined use of vasonatrin and gastrin-i as a therapeutic agent |
| 04/16/2009 | WO2009046872A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046868A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046867A2 Caerulein alone or in combination with acth (3-24 ) as therapeutic agent |
| 04/16/2009 | WO2009046866A2 Trap-14 as a therapeutic agent |
| 04/16/2009 | WO2009046865A2 Cholecystokinin-33 alone or in combination with trap-14 as therapeutic agent |
| 04/16/2009 | WO2009046864A2 Use of the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046863A2 Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046862A1 Use of physalemin as a therapeutic agent |
| 04/16/2009 | WO2009046861A1 Use of cnp-22, alone1 or in combination with physalemin, as a therapeutic agent |
| 04/16/2009 | WO2009046860A2 Use of dago as a therapeutic agent |
| 04/16/2009 | WO2009046859A2 Use of af12198 and dago as therapeutic agents |
| 04/16/2009 | WO2009046858A2 Therapeutic uses of kisspeptin 13 and compositions thereof |
| 04/16/2009 | WO2009046857A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046856A2 Use of serorphin as a therapeutic agent |
| 04/16/2009 | WO2009046853A1 Use of intermedin 47 peptide as a therapeutic agent |
| 04/16/2009 | WO2009046852A1 Therapeutic uses of intermedin 47 and 53 peptides |
| 04/16/2009 | WO2009046851A1 Cgrp as a therapeutic agent |
| 04/16/2009 | WO2009046850A1 Cgrp as a therapeutic agent |
| 04/16/2009 | WO2009046849A1 Use of the peptide cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046848A1 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046847A2 Use of peptide ll-37 as a therapeutic agent |
| 04/16/2009 | WO2009046846A2 Use of il-1 receptor peptide, alone or in combination with peptide ll-37, as a therapeutic agent |
| 04/16/2009 | WO2009046845A2 Use of a lactoferrin partial peptide peptide as a therapeutic agent |
| 04/16/2009 | WO2009046844A1 Therapeutic uses of peptide tdvngdgrhdl |
| 04/16/2009 | WO2009046843A1 Therapeutic uses of peptides kvlpvpq and/or tdvngdgrhdl |
| 04/16/2009 | WO2009046834A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |